{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-23-000048","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.506234+00:00","generated_at":"2026-06-11T14:32:01.324919+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elicio posts Q2 net loss $7.6M, cash $21.7M; reports interim AMPLIFY-201 data","bullets":["Net loss $7.6M ($2.61/share) vs $7.3M; cash $21.7M at June 30 vs $6.2M at Dec 31, 2022.","R&D expense $4.9M, G&A $2.8M (up vs $1.2M) due to reverse merger and public company costs.","AMPLIFY-201 interim data: ELI-002 induced mKRAS T-cell response (56-fold avg); tumor biomarker reduced in 77% of patients.","AMPLIFY-7P Phase 1A enrollment initiated for ELI-002 7P; Phase 1B RP2D initiation expected Q3 2023.","Completed reverse merger in Q2 2023; common stock now trading on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-23-000048","json":"https://secwatch.observer/filing/0001601485-23-000048.json","markdown":"https://secwatch.observer/filing/0001601485-23-000048.md","text":"https://secwatch.observer/filing/0001601485-23-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148523000048/0001601485-23-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148523000048/angn-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:32:01.324919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5015708d7ff379839c63f8961d0448bd9808580a","claim":"Elicio Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $7.6 million, EPS Net loss per share for the second quarter of 2023 was $2.61.","evidence_excerpt":"Elicio Therapeutics, Inc. (the \"Company\") announced its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148523000048/0001601485-23-000048-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the second quarter of 2023 was $7.6 million"},{"label":"EPS","value":"Net loss per share for the second quarter of 2023 was $2.61"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}